Objectives: To examine the relationship between the recently defined Gleason grade groups and prostate cancerspecific mortality.
Conclusions: Although using the original study patient population may require years of additional follow-up to examine prostate cancer-specific mortality, the evidence available now indicates that these new Gleason grade groups relate to prostate cancer-specific mortality.
Fifty years have passed since Gleason introduced his grading scheme for prostate cancer. [1] [2] [3] He developed this system before the serum prostate-specific antigen (PSA) test, before multiple 18-gauge needle biopsies, before immunohistochemical stains, and before the Cox proportional hazard survival analysis were available. 4 Relying on his experience with a variety of prostatic tissues from patients with all stages of tumor, he intuited several histologic patterns of tumor as important. Then as a reviewer for several Veterans Administration prospective studies, he and the statisticianepidemiologist John Bailar connected these histologic patterns to survival outcomes. Because the studies were conducted before the PSA era, most of the patients were symptomatic, and many had more than localized disease. More than a few had fatal disease, so that his study patient population differed from those commonly encountered today Table 1 . The success and longevity of his grading system has been impressive, and by 1979, his system was chosen to be the standard. 5 Then, in 2005, a group of 80 pathologists interested in prostate cancer convened to reevaluate Gleason's grading scheme. Based on their collective experience and some publications after 1990, they changed the grading system. 6 More recently, a second group of 65 pathologists convened in 2014 to formulate a grading scheme simplified into five groups, and this formulation was derived from follow-up studies of more than 20,000 patients from five academic institutions. 7, 8 Table 1 compares the recent grading scheme and the related study with those of Gleason. The details demonstrate how the study patients differed as well as how some categories of grade were changed. Two differences between Gleason's original work and the recent one are striking. First, the recent study patients had a lower clinical stage, and all were treated with prostatectomy or radiotherapy. Second, in the recent study, the end point was biochemical failure rather than prostate cancer-specific death. This end point was necessitated because it would take an additional 10 to 15 years of follow-up to obtain the stronger end points of metastatic tumor or prostate cancer-specific death. 8 Because the authors of the recent study cited the biochemical failure end point as a "major limitation" of their study, here I associate the new grade groups to prostate cancer-specific death through the use of a probabilistic model and prior data connecting biochemical failure to prostate cancer-specific death. To take advantage of the most accurate Gleason grading and the maximum amount of tissue and patient data available, I restrict this analysis to those undergoing prostatectomy. The results suggest that the new grade groups relate to prostate cancer-specific death.
Materials and Methods

Probability Model
The starting assumption is that biochemical failure (BF) precedes prostate cancer-specific death (PSD). In other words, we assume that the conditional probability of PSD given the absence of BF is zero. Mathematically, this assumption is written as
With this assumption, the probability of PSD can be written as
Data for P(PSD j BF) are available for patients after prostatectomy and for this study were taken from three publications. [9] [10] [11] Specifically, the reported survival curves, symbolized here as S a (t) for times t after BF, were digitized, and the number of patients who failed at each time, nf, was estimated as
where na(t) symbolizes the number of patients available at time t, and Dt symbolizes the time interval. The number of patients censored, nc, during the time interval was taken to be
In this fashion, the number of failed and censored patients from each of the three studies and each follow-up time was estimated. In other words, the reported survival curves were transformed into individual patients' times of failure and censoring so that overall differences in the amount of follow-up between the three studies were accounted for. Then the composite overall survival function, S a (t), was estimated with the Kaplan-Meier function. Figure 1 shows this combined survival curve, which was derived from a total of 3,478 patients who had biochemical failure. The smooth curve comes from a fitting function, which was used for the convenience of plotting and subsequent calculations (see below). Finally, P(PSD j BF) for any given time, t, after biochemical failure was taken to be
P(BF) was estimated by digitizing the postprostatectomy survival curves published by Epstein et al 8 for each of the five grade patterns, and once again for convenience of plotting and subsequent calculations, a fitting function was used to represent S b (t) for each pattern. Finally, P(BF) at any time after prostatectomy was taken to be
The Fitting Function for S(t)
In general, any survival probability, S(t), relates to the hazard function h(t) as follows 12 :
where exp stands for exponentiation and where the integration limits for x are from 0 to t. As before, the hazard Figure 1 A plot of the probability of surviving after biochemical failure. The plot was derived from a total of 3,478 patients reported in three studies. [9] [10] [11] The smooth curve comes from a fitting function (see text). PSA, prostate-specific antigen.
function h(t) was modeled as the sum of two gamma functions, h1 and h2, as follows 12 :
and a, b, k, and d were derived to provide least squares fits to S(t). This approach provided a concise way to represent the six survival curves used here and a convenient way to obtain continuous plots vs times of follow-up. Figure 2 demonstrates the accuracy of the model with a plot of observed values of S(t) vs those predicted by equations 7 to 9.
The line on the plot shows where perfect agreement would occur, and the fact that the points lie close to the line indicates that this model fit the observed survival curves very well. The mean difference between observed and predicted values of S(t) was -.0038 (range, -.016 to .014).
Results
Using equation 5, the probability of fatality within 10 years of biochemical failure was 0.19, that is, the combined data from the studies reporting P(PSD j BF) found that just 19% were expected to die of prostate cancer within that time interval. Alternatively, this result suggests that in general, more than 80% can be expected to survive at least 10 years after biochemical failure. Figure 3 shows the expected probability of prostate cancer-specific death within 10 years after biochemical failure vs years of follow-up. The expected probability was calculated from equation 2, and the time on the x-axis reflects more closely the times of biochemical failure than the expected times of death, which was expected to occur at otherwise unspecified times within 10 years after biochemical failure. The numbers on the curves provide the grade groups. The steep rises in the three topmost curves during the first year of follow-up suggest that for those with tumors in grade groups 3 to 5, there are men who have early biochemical failure and who are at increased risk of eventual prostate cancer-specific death. After this time, the curves plateau. Figure 4 summarizes the results of Figure 3 , and together both plots demonstrate that the expected probabilities of prostate cancer-specific death in the span of 10 years following biochemical failure increase steadily with the new grade groups.
The early and rapid rise in the three topmost curves of Figure 3 can be examined further via the hazard functions for biochemical failure, which are plotted vs years of follow-up after surgery Figure 5 . The lowest and nearly flat line is for grade group 1, and the sequence of higher lines are for grade groups 2 to 5, as noted on the plot. Clearly, the peak hazard increases as the grades increase, implying that the proportion of men who experience biochemical failure rises with each grade group. In addition, the plots demonstrate that the timing of peak hazard for biochemical failure for grade groups 2 to 5 is close to one another, at approximately 5 months after surgery Table 2 . By contrast, the hazard for grade group 1 peaks at approximately 3 years and remains nearly flat. Altogether, these hazard results suggest that for grading groups 2 to 5, there are men with rapidly rising PSA (ie, short doubling times), and the results for grade group 1 support the notion that these tumors are indolent. 8 
Discussion
The probability model used here (equation 2) is a product of two probabilities, P(PSD j BF) and P(BF), and a weakness of this approach is that the first was derived from three studies while the second was derived from a fourth. Specifically, P(PSD j BF) was derived from three earlier studies collectively involving 3,478 patients who were followed after biochemical failure.
9-11 P(BF) was derived from the recent study introducing and validating the simplified five groups of Gleason scores. 8 Because the three studies used for estimating P(PSD j BF) were done before the new grade groups were introduced and because none of these adjusted their survival curves for grade, differences due to grade could not be accounted for. Thus, only a composite curve for P(PSD j BF) could be formed. However, I believe that the large numbers of patients used (n ¼ 3,478), the overall averaging process, and the reliance on the delayed starting point of biochemical failure (rather than time of treatment) were sufficient to provide a reasonable estimate for P(PSD j BF). Furthermore, all four studies used large numbers of patients who underwent prostatectomy, and all came from respected academic institutions. Using this model, the results document a strong association between the recently formulated grade groups and expected prostate cancer-specific mortality within 10 years after biochemical failure. The magnitude of expected mortality rates is not high and ranges from 1.4% to 15%. The differences in expected mortalities among the grade groups are also small, and this suggests that follow-up studies on the original study population may be underpowered to demonstrate significant between-group differences in prostate cancer-specific death rates. For example, Schoenfeld's algorithm 13 suggests that to detect a difference in prostate cancer-specific mortality between grade groups 4 and 5 would require 6,054 patients to reach a P value of .01 with a power of 80%. Yet, in the original data, only 1,968 patients were present, and by 10 years, censoring had dropped the number to 9. Similarly, to detect a difference in prostate Figure 4 A boxplot summarizing the range (uppermost and lowest lines), 25th and 75th percentiles (solid box), and medians (white horizontal bars) of the expected probabilities of prostate cancer-specific death within 10 years after biochemical failure (y-axis) according to the five grading groups (x-axis). PSA, prostate-specific antigen. Grade groups are defined as follows: group 1, Gleason score 6; group 2, Gleason score 3 þ 4; group 3, Gleason score 4 þ 3; group 4, Gleason score 8; and group 5, Gleason score !9. The time of peak hazard for biochemical failure is given as years after surgery. The median and maximum refer to expected 10-year mortality rates as follow-up progresses. For example, for a median follow-up time of 5 years, some men will have biochemical failure, but more will fail with a follow-up of 10 years. Thus, the expected mortality rises as follow-up lengthens to reach the maximum expected mortality in the last column (see also Figure 3 ).
cancer-specific mortality between grade groups 3 and 4 would require 15,318 patients to reach a P value of .01 with a power of 80%. Yet, in the original data, only 4,022 patients were present, and by 10 years, censoring had dropped the number to 22. The approach using equation 2 avoids the power issues as well as the need to wait another decade to obtain results, and it offers, for the moment, a way to estimate how the five new grade groups relate to prostate cancer-specific death.
